Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

August 6, 2020

NASDAQ US Health Care Life Sciences Tools and Services earnings 65 min

Earnings Call Speaker Segments

Jacquie Ross

executive
#1

Good afternoon, everyone, and thank you for being with us to discuss the results for the second quarter of 2020. On today's call, we'll go over the financial figures that were published following the market close, and we'll also provide some commentary regarding our commercial activity. After that, we'll open things up for a question-and-answer session. Should you not yet have had an opportunity to look at the earnings release, you can locate it on our website, illumina.com, under the Investor Relations section. Joining us from Illumina today are Francis deSouza, our President and Chief Executive Officer, and Sam Samad, our Chief Financial Officer. Francis will provide an update on the business, and Sam will walk through our financial results. As was the case last quarter, we are hosting this call from several different locations, so we ask for your patience should any technical difficulties or pauses arise. This call is being recorded, and the audio portion will be archived in the Investors section of our website. It is our intention that all forward-looking statements about our financial results and commercial activity made on today's call be protected under the Private Securities Litigation Reform Act of 1995. Forward-looking statements carry risks and uncertainties. Actual events or results could differ materially from those projected or discussed. All forward-looking statements rest on information currently available, and Illumina undertakes no obligation to update these statements. To gain a better understanding of the risks and uncertainties that might cause actual results to differ, we point you to the documents Illumina files with the Securities and Exchange Commission, including Illumina's most recent Forms 10-Q and 10-K. With that, I'll hand the call over to Francis.

Francis deSouza

executive
#2

Thanks, Jackie. Hello, everyone, and I appreciate your joining us this afternoon. As anticipated, Q2 proved difficult when measured against what we originally laid out for 2020; even so, it was a period of solid execution given today's conditions, and it leaves us on firmer footing for growth down the road. It has made me proud to watch our staff adapt and bend to serve customers, to see us accelerate what was already a vigorous innovation machine, and to see how we've looked after one another in our communities during this pandemic. While we work through the short-term turbulence, our attention stays on the far-off potential for Illumina and for sequencing, which is, if anything, bigger now than 6 months back. To recap our Q2 results and what lies ahead. Revenue in the second quarter came to $633 million, a decline of 25% versus the prior year, since customers worldwide keep feeling the effects of the pandemic. We're noticing signs of a slow rebound and, assuming nothing unforeseen happens with how the pandemic unfolds, Q2 ought to mark the lowest revenue point of the year. On top of that, we anticipate quarter-over-quarter revenue gains in Q3 and Q4. Next, even with fewer patient visits, our clinical segment is holding up better than research, which keeps taking a bigger hit from the shelter-in-place rules still in force. Third, infectious disease is turning into another area of long-term emphasis for genomics. Illumina moved fast with three workflows, among them software tools and COVIDSeq, our COVID-19 diagnostic test, which traveled from idea to authorization in under 60 days. Because of when these arrived, they added only a slight amount to Q2 revenue, and the level of interest we're witnessing so far in Q3 is heartening. Last, and above all, we think the long-term potential for sequencing keeps growing. Although COVID-19 has hurt our customers' capacity to operate in the short run, going through this together is widening awareness and deepening appreciation of what genomic insights can do. Studies, among them GEL's 35000 patient study in the UK, might in the end speed up adoption of genomic tests into routine clinical use for infectious disease and surveillance. Turning specifically to the back half of 2020, sequencing consumables, which account for the bulk of what we bring in, are still tied to shelter-in-place activity, so any rebound hinges on how fast customers return to their labs. Even so, the momentum we see as we head into the latter half of the year gives us encouragement. Sequencing consumable run rates are climbing, and certain clinical customers sit at or beyond their run rate from Q4 of last year. Sequencing system placements rose quarter over quarter, helped by more NovaSeq shipments. In addition, NextSeq 2000 shipments surpassed what we had expected for Q2. Population genomics efforts keep advancing. All of Us, for instance, has gotten the IDE it needed from the FDA, and later this quarter we will begin sequencing and genotyping. Also, outside of research, sequencing tied to COVID-19 for both diagnosis and screening sits earlier in its adoption curve and might expand much more substantially during the back half of the year. Understanding the SARS-CoV-2 virus, how the pandemic transmits, how effective treatments and vaccines get developed, and how host and virus interact when it comes to transmission and virulence — sequencing keeps playing a vital part in all of that. On top of that, interest keeps building in using sequencing to help meet the demand for greater diagnostic and screening testing capacity. To add to testing capacity, Illumina moved urgently to create COVIDSeq, the first NGS-based diagnostic for COVID-19. Emergency use authorization came to us from the FDA on June 7, and we transitioned to a handful of early access customers near the close of the second quarter. <<inaudible>>, for instance, plans to launch near the end of this quarter and expand through the close of 2020. COVIDSeq operates on our NovaSeq and, beyond a yes or no diagnosis, delivers a complete viral sequence for the majority of positive samples; such information may prove essential for grasping community transmission patterns so regional outbreaks can be controlled better. We keep broadening what COVIDSeq can do through a set of amendments that will introduce saliva, boost automation and reduce supply chain risk; right away, we have filed an amendment to the existing authorization for our current COVIDSeq test that streamlines the workflow, adding another RNA extraction method to lower supply chain risk and extending the test past our NovaSeq by incorporating NextSeq. That will let labs with lower throughput provide COVID-19 diagnostic testing in their own areas, which might complement today's PCR test providers, who face turnaround times reaching 10 business days. Going forward, as Illumina's COVIDSeq supply ramps up, we are talking with dozens of customers across more than 10 countries, and several of them are actively assessing COVIDSeq. As an example, the Institute of Genomics and integrative Biology in New Delhi has just finished its initial clinical validation of COVIDSeq and reported sensitivity above 98% along with a diagnostic yield gain of 8% to 10% relative to PCR. The team finds COVIDSeq appealing as a way to boost front-line testing availability while also obtaining viral genome data usable for tracking how the virus spreads; alongside COVIDSeq, we are glad that Ginkgo and Helix numbered among the 7 funding recipients from the NIH's rapid acceleration of diagnostics initiative. This highlights how sequencing based diagnostic tests could scale and widen testing past PCR, something we think will grow more and more important as the fall flu season approaches. Turning to screening; how broadly screening programs get adopted is still unclear; even so, it is evident that a number of programs will scale during the third quarter. During the previous week, Testing for America revealed a collaboration with historically black colleges and universities aimed at creating return-to-campus programs for academic institutions in the Thurgood Marshall College Fund and the United Negro College Fund Family. As an illustration, Delaware State University launched its pilot screening effort a few weeks back, intending to screen as many as 3,000 students and educators each week. Moving to the quarter, beginning with regional outcomes. Every region felt the effects of extended shutdowns or diminished activity at research labs, and in certain instances, from short-term shifts of resources toward PCR testing for COVID-19. Revenue in China declined by $5 million compared to the prior quarter, matching what we anticipated as a fairly small decrease. COVID-19 challenges stemmed from the research sector, with longer-lasting closures at certain universities and research institutes, which we foresee persisting into the third quarter. Clinical, on the other hand, proved somewhat resilient throughout the pandemic, expanding both quarter-over-quarter and versus the same period last year, fueled by reproductive health. Oncology testing remains under pre-COVID-19 figures, though it is getting better. EMEA revenue reached $168 million, mostly aligning with what we expected, and showed notable quarter-over-quarter drops in both research and clinical sequencing consumables. Research difficulties arose from labs shutting down, while certain other customers shifted resources toward COVID-19 diagnostic testing not based on sequencing. As anticipated, the Americas region experienced the biggest quarter-over-quarter dollar hit from COVID-19, falling $142 million from the prior quarter to $335 million.

Francis deSouza

executive
#3

In contrast with April, a greater number of academic and government laboratories are restarting work, yet the majority continue to run far under where they stood before COVID-19. Clinical remains the more durable area, though certain customers have noted reduced clinical samples tied to shelter-in-place measures. Last, Asia-Pacific brought in revenue of $51 million, versus $57 million during 2019's second quarter, as research labs cut back on activity. Turning to the customer perspective, we keep monitoring sequencing run rates as a signal of overall activity, though we caution that this does not move in direct lockstep with revenue; it's evident that as customers work through this pandemic, plenty are holding less sequencing consumable inventory than they used to. Consequently, shipments—and hence revenue—trail the rebound we observe in run rates. Even so, on the clinical side, we noted that run volume at April's close stood at roughly 80% of last year's fourth-quarter run rate. Clinical run rates across this year's second quarter averaged 84% of the Q4 '19 run rate. The pattern shows modest improvement, yet swings considerably from one week to the next. Inside clinical, reproductive health remains the most durable category, with Oncology next. Shifting to research, the second-quarter run rate climbed from roughly 55% at April's end to roughly 65% of the Q4 '19 run rate, though it plainly is still heavily affected by the pandemic. Week-to-week run rates for research customers fluctuate more than clinical ones. Although commercial disruption could not be avoided, the wider Illumina team keeps delivering on our strategic priorities through new product launches and acquisitions meant to further strengthen our customers' application portfolio, improve ease of use, and widen our market opportunity. Initial response to NextSeq 2000 has been highly favorable, with customers saying these sequencers exceed expectations, delivering the outstanding data quality they have long expected from Illumina. Even with the move to a virtual environment, our team has performed admirably at installing new systems and getting customers operational, which reflects the strength of our support organization along with the engineering and product design underneath. On top of that, customers continue to express interest in the P3 flow cell, which is still slated to launch in the fourth quarter. As mentioned previously, we secured the first emergency use authorization for a sequencing-based COVID-19 diagnostic test in early June, underscoring our flexible R&D and regulatory abilities; in early July, we introduced the TruSight Software Suite for genetic disease, which lets labs shorten the time to potentially transformative genomic insights from weeks down to hours. The TruSight Software Suite assists customers in rapidly sifting through millions of variants to pinpoint difficult-to-find genomic conditions; we think this TruSight Software Suite might eventually form part of a new standard of care for newborns with a suspected genetic condition. Moreover, broad and expanding reimbursement is already available for genetic disease testing. With clinical sequencing demand expanding, we keep pinpointing and resolving obstacles that stand in the way of uptake, and that work has driven new ideas throughout the whole sequencing process. Just recently, we introduced our fresh DNA PCR free prep, cutting the time needed for library prep by up to 75%. That shortens the wait for results and boosts lab productivity, both of which matter even more when it comes to clinical samples. Over at the opposite end of the process, we keep searching for ways to assist our customers in storing, managing, and analyzing the enormous volumes of data our sequencers produce; keeping that goal in view, we completed two technology acquisitions during June and July that, alongside our current software offerings, made data processing and sharing more efficient and scalable. BlueBee provides software that strengthens what users can do to pull insights out of genomic data kept in Illumina's analytics platform, while Enancio supplies proprietary lossless genomic data compression software that shrinks storage footprint by a factor of five and will be folded straight into the Dragon workflow. Beyond the sequencing process, though still significant, we got encouraging responses to our new sustainable reagent packaging, which will keep close to 250,000 cubic feet of foam packaging out of landfills annually. Last, I'm happy to share news of some upgraded features and fresh pricing for our NovaSeq reagent kits. These updated reagent kits provide a longer shelf life plus extra cycles, stretching our performance advantage in the high throughput market. On top of that, the new kit brings more affordable pricing to every NovaSeq user, putting the $600 genome within reach of all our customers. Such changes reflect Illumina's continued dedication to sequencing innovation so as to allow deeper sequencing, the uptake of more data intensive applications such as whole-genome sequencing, single cell and liquid biopsy, and bigger cohorts to boost the statistical power of studies. With that, I'll pass things to Sam so he can go through the financials in greater detail.

Sam Samad

executive
#4

Appreciate that, Francis. As we talked about, Q2 revenue fell 25% compared to the same period a year ago, landing at $633 million, because the pandemic hit our research-focused customers hardest. Revenue from sequencing systems overall came to $88 million, a bit above what we'd projected, helped by NextSeq 2000 shipments coming in stronger than anticipated. We shipped more NovaSeq, NextSeq 2000, MiSeq, and MiniSeq units than in the prior quarter. Adoption of the NextSeq 2000 keeps spreading across a wide variety of clinical and research uses, such as oncology testing, single cell, molecular pathology, and infectious disease, including COVID-19 Research. During Q2, the bulk of NextSeq 2000 placements came from customers converting from older NextSeq instruments, and in total so far, about one quarter of these new systems have gone to buyers who are new to Illumina. Consumables revenue for sequencing reached $387 million, with plenty of customers still running at volumes beneath where they were before COVID. One notable point: clinical sequencing consumables made up nearly 50% of all sequencing consumables, since research customers have been hit harder by the pandemic. Sequencing service and other revenue totaled $91 million, down from the previous quarter because of reduced licensing revenue, and down versus a year ago because sequencing service revenue was lower. All told, sequencing revenue came to $566 million, which was 89% of total revenue. Array revenue overall was $67 million, a 39% drop from the same quarter last year and a 32% drop from Q1 of 2020, partly reflecting our reduced outlook for the DTC market and its usual seasonality, plus headwinds tied to COVID-19. Turning to the P&L, as I always do, I'll point to non-GAAP results, which include stock-based compensation. I'd urge you to look at the GAAP reconciliation for these non-GAAP measures, available in today's release and the supplementary data on our website. Keep in mind that any later mention of net income and earnings per share refers to results attributable to Illumina shareholders. Non-GAAP gross margin came in at 68.6%, lower as anticipated both versus last year and versus the prior quarter. That reflects reduced revenue, which meant less leverage on fixed costs, along with higher freight costs tied to the pandemic. Non-GAAP operating expenses were $334 million, which is $5 million less than Q1 of 2020 and $26 million below Q2 of 2019; this came in under expectations because of an adjustment to stock-based compensation expense reflecting updated EPS projections. Non-GAAP operating margin was 15.8%, down from 33.6% in the prior quarter. The non-GAAP tax rate was 18.5%, higher than last quarter and the prior year, driven by a greater income mix in jurisdictions with higher tax rates. For Q2 of 2020, GAAP net income was $47 million, or $0.32 per diluted share, while non-GAAP net income was $92 million, or $0.62 per diluted share. On a per share basis, our GAAP results include $0.61 for two discrete tax expense items. One item concerns a valuation allowance we set up against the deferred tax asset tied to California R&D tax credits, and the other stems from the Altera court case being finalized, which held that share-based compensation has to be counted in intercompany cost-sharing payments; other income offsets this partly, adding $0.38 per share, and that figure includes $69 million of unrealized gains on equity investments. On top of that, during the second quarter, operations generated $240 million of cash, capital expenditures came to $38 million, and free cash flow reached $202 million. DSO was 55 days versus 50 days in the prior quarter, driven partly by revenue linearity that was less favorable along with lower revenue. We bought back $143 million of common stock. As a result, we closed the quarter holding roughly $3.3 billion in cash, cash equivalents and short-term investments. Our weighted average diluted share count for the quarter came in at approximately 148 million. Under the plan we currently have, $420 million remains available for share repurchases. Also, our 2021 notes turned convertible between July 1 and September 30, 2020. Keep in mind that since the second quarter of 2018, the dilutive effects of the convertible notes have been baked into our diluted average share count. Our view remains that because of the uncertainty surrounding how severe and how long the COVID-19 pandemic will be, and what it means for our research customers especially, offering quarterly or full year outlooks is difficult right now. Speaking directionally, we can say that for our clinical customers we anticipate sequencing run volumes will improve modestly from the 84% we reported in the second quarter. On the research and applied side, we stay cautious, and we anticipate run volumes will rise modestly above the 65% reported in the second quarter. Sequencing instrument revenue should grow modestly quarter over quarter, and we expect the re-revenue to be flat to slightly up. Looking at regional performance, we anticipate sequential growth across every region in the third quarter. Although certain regions are bouncing back faster than others, headwinds will certainly be present in all regions, and measured against the third quarter of 2019, we anticipate lower revenue in every region except APJ, which should come in about flat. For the third quarter of 2020, we anticipate non-GAAP EPS will be modestly higher than in the second quarter of 2020, reflecting revenue improving gradually, a sequential drop in non-GAAP gross margin driven partly by the second quarter's adjustment to stock-based compensation and more field service activity as labs reopen, plus a rise in non-GAAP operating expenses driven mainly by the second quarter's adjustment to performance-based compensation. Even though we anticipate operating expenses will increase sequentially in the third quarter, we stay thoughtful and deliberate regarding where we put our money. That means we keep investing in R&D projects and use our balance sheet to chase growth opportunities. In our position at the forefront of genomic technology, we feel a duty to keep putting money into innovation even when near-term revenue faces obstacles. Yet simultaneously, we'll strike a balance elsewhere by halting or pushing back some capital expenditures and capping additional discretionary spending. So with that, I'll now return the call to Francis.

Francis deSouza

executive
#5

Thanks, Sam. Sure, the short-term turbulence is tough while we keep steering through the pandemic, but our confidence in what lies ahead for Illumina hasn't wavered at all. As demand grows for stronger capabilities in infectious disease research and surveillance, the broader sequencing opportunity keeps getting bigger. Innovation is still our guiding light, and we'll keep working alongside our customers while also developing things in-house, so that applications built on sequencing play a part in worldwide efforts against this pandemic — and in whatever mix of research, diagnostics, screening and surveillance applications delivers the greatest impact. Our competitive standing is solid, with the recent preliminary injunction helping safeguard our intellectual property here in the United States. And beyond the pandemic, our dedication to innovation stays firm, as does our commitment to invest appropriately so we can advance our technology pipeline and keep bringing gold standard sequencing products to market. I want to thank our customers and our employees, who are showing resilience and flexibility as we get through this pandemic together; with that, let's begin the Q&A.

Tycho Peterson

analyst
#6

Hey, thank you. Francis, I realize you haven't provided guidance, but could you help us quantify a few aspects of the COVID testing opportunity? You mentioned that scaling up more significantly in the latter half of the year, along with the dozen customers and 10 countries. I'm curious whether you can offer any framework for how you're viewing that ramp-up and the size of that opportunity. In a similar vein, regarding PopSeq — early in the year, you mentioned 280,000 genomes, and clearly there have been setbacks, but I'm wondering if you could update us on what share of those you believe will be completed in the back half. Lastly, on China: it dropped 19%, and that surprised us somewhat, given the rebound underway in that market. Could you speak to that, and also to when it might return to expansion? Thanks.

Francis deSouza

executive
#7

All right. We'll go through these individually, Tycho. To start, let's talk about COVID and what kind of ramp we expect during the second half. As stated in the prepared remarks, COVID-related revenue in Q2 was minimal, and we expect it to start accumulating as we move through the latter part of the year. When we put together our base case, we're assuming there won't be much certainty around COVID-related revenue in Q3. That said, there are a number of areas where customers want to apply sequencing, and we expect those to start bringing in revenue during Q3 before building up further in Q4. Research, diagnostics, screening, and surveillance are the areas in question. On the research front, a number of projects launched in Q2 and should start scaling across Q3 and Q4. One illustration is what's taking place in genomics — for instance, the UK NHS GEL project, which involves looking at 35,000 COVID patients and sequencing them in order to figure out what drives how severe the infection becomes. You've also got initiatives such as GMI and Canada's CanCOGeN. When it comes to Diagnostics, quite a few of our customers are beginning to expand what they can do on that front — names like Ginkgo, Helix, and Garden to UCLA, for instance, have all just kicked off that expansion, and we're expecting them to start scaling during Q3 before ramping further in Q4. Beyond that, certain customers are exploring the launch of a screening-focused product tied to Back to School or Back to Work programs. Take Delaware State University, for instance — as I noted earlier, they've teamed up with one of our customers to test roughly 3,000 teachers and pupils weekly, all aimed at bringing people back to campus without risk. Whether those initiatives expand across Q3 and Q4 remains to be seen, and the range of outcomes is broad, as you'd imagine — should it genuinely be embraced as a way to get kids into classrooms safely, it could end up being quite substantial. Beyond that, several monitoring efforts are now getting underway that aim to assist with tracking how the pandemic spreads, and they're also trying to build systems that will endure once this pandemic is over; take, for instance, the work being done with the CDC, setting up a monitoring framework. So those make up the four categories. We have research, we have diagnostics, screening and surveillance — once again, revenue from these has been minimal up to now, but it's beginning to build in Q3 and moving toward the close of the year. That covers the first question. Now for the second one, it concerned PopGen <<inaudible>>, so let me discuss a few of the major programs. When it comes to All of Us, we recorded no sequencing revenue tied to it during Q2 <<inaudible>>, yet things moved forward — they got the IDE from the FDA and intend to begin expanding in Q3, followed by a more substantial expansion in Q4. The UK NHS has truly concentrated its efforts — it has halted the project it previously had, and now its attention is squarely on the GEL-related effort I mentioned a moment ago. The UK Biobank did sequencing during Q2, though its run rate was considerably lower than in Q1, and we anticipate that it will keep growing throughout the year. As for China, which I believe formed the final portion of your question, it declined, and what we observe there is a genuine obstacle in the research sector, where even though China is somewhat finding its way back to normal, a pattern persists in which many academic labs are either shut or running with reduced staff or have been redirected toward COVID-related testing. Consequently, the research sector in China remains in decline. That said, we're noticing greater stability in China coming from the clinical sector, so we saw positive results both in the NIPT portion of the business and in oncology, when compared with the research sector.

Sam Samad

executive
#8

Right. And on the clinical side in China too, Tycho, I'd just add that we are actually seeing growth both sequentially and year-over-year. That showed up in Q2, so there's definitely resilience in the clinical part of the Chinese market, though research has been hit hard by the closures. The resurgence in Beijing as well, along with the closures tied to it, didn't help matters in the quarter either.

Steve Beuchaw

analyst
#9

Good afternoon, and I appreciate you making room for me. There are a couple of items I'd like to raise. The first one falls into the academic category, and the second one concerns what I'd describe as forward-looking signals. On the academic side, I believe everyone here grasps reasonably well why conditions are so difficult at the moment, correct? This has nothing to do with Illumina — it's simply the state of the world today. What I'm curious about, though, is your thinking on how much of this reflects demand being wiped out rather than demand being pushed back. Let me expand on that a bit. In many instances the funding exists, yet gaining access to the lab is difficult — does that imply these projects are merely being postponed to some future date? And how worried are you about the funding itself, considering the difficulties universities face — although I'm not certain that represents your entire academic funding base, so to speak. Then the second item I'd like to discuss, or rather ask about, Francis, is this: near the beginning of your prepared comments, you remarked — or at least implied — that at some future point, as a consequence of all the current circumstances, you believe the TAM ends up bigger. So I'm hoping you could expand on that. I'm sure you've already addressed many of the relevant points, but how do you actually monitor it? What are you observing on a daily basis, or is it largely gut feeling? What are the forward-looking signals? How do you keep tabs on this notion that the TAM really is bigger? Are there project metrics, quote activity you examine that provide insight into what sequencing activity will probably look like some number of weeks, months, or quarters ahead, that you'd be comfortable sharing with us? Thank you.

Francis deSouza

executive
#10

Certainly, Steve. I appreciate the question. It breaks into two components. The first component concerns what we anticipate will occur in academic markets regarding research funding, and whether we think projects will be postponed or scrapped, along with how we're approaching that question. What we're hearing from customers, Steve, is that projects are being postponed rather than scrapped — they're being postponed because either individuals are working from home under shelter-in-place measures and can't perform the research they need to do at present, or they are present in the lab but have been <<inaudible>> toward non-sequencing COVID-related work. However, they're informing us—despite this—that their plan is to resume those research initiatives, and even when a funding deadline exists for such projects, quite often those dates are getting extended so they can return and continue the work. Consequently, what we're clearly hearing back from our client base is that those initiatives have been halted and they anticipate restarting them. Furthermore, what customers in the research field are telling us is that extra money is entering the picture because of the pandemic. So, what they're observing is funding being directed toward genomics studies tied to the pandemic—whether that involves the host response, for instance, or figuring out why certain individuals suffer more severely from the illness, or a wide range of other factors—which is pushing additional dollars into the research sector. Thus, they're currently considering how to organize those initiatives. Also, they're reporting to us that initial indications regarding NIH budgets, such as in the US, are quite favorable—that the preliminary proposals involve a rise of roughly $5.5 billion for the NIH budget, on a base of approximately $47 billion. So that's a fairly significant boost in the initial proposal. And that covers items like COVID-related efforts, but it additionally suggests a funding boost for NHGRI, which is plainly tied to genomics programs. Therefore, regarding academic research, the signs of a recovery appear quite encouraging to us at this moment. That's partly why we launched the $600 genome—because we want people, as they consider the projects they'll undertake and return to, to handle them suitably and expand their sequencing since they can now design bigger projects with deeper sequencing or larger cohorts. So there's certainly plenty of deliberation about what they'll do upon returning. That addresses the first portion of your question. The second portion concerned how this affects Illumina's addressable market. What has the pandemic's effect been? It's growing evident to us that Illumina's total TAM has grown in recent months—if you'd spoken with us even in January, or definitely by December or earlier, we'd have discussed far more the clinical opportunity in oncology and reproductive health, but hardly anything about infectious disease. And obviously, that has truly shifted in recent months. What's turning out to be quite apparent is that genomics has a part to play in numerous infectious disease areas. Genomics already had a part to play, and it's expanding within research. So infectious disease research involving genomics has been around, but it's genuinely beginning to grow as we head into the next several months and quarters, tied to some of the areas I mentioned — such as grasping the virus itself, and grasping how the virus and the host interact. On top of that, genomic testing is genuinely needed in diagnostics. That's pretty new, correct? Had we spoken a few months back, we'd have described the infectious disease diagnostics sector as mostly a PCR sector, and looking ahead, that is shifting. Sequencing-based diagnostic capability is going to reach the market thanks to our customers such as Ginkgo or Helix <<inaudible>>, and going forward that will be a significant piece of the diagnostic testing sector, and that's new and that's genuine; we're also watching customers investigate a considerably bigger opportunity around screening, and we're at an early stage there, and you've heard about what's taking place at Delaware State University; but that stands for a completely fresh opportunity around considering how you build safe environments in schools and work, and that's a fresh segment of the market becoming reachable for genomics; and lastly, there's a surveillance opportunity, and this, I believe, is durable, since it's growing very obvious that a global pathogen surveillance network is needed, one that's genomics based, that a much improved early warning system is needed to know whether a viral outbreak is occurring, and that might be for things such as the Coronavirus right now, but going forward, it's required for things such as antimicrobial resistance, for bio terrorist attacks, say, and so an early warning system is needed. A network system is needed that grasps the transmission and virulence of the pathogen as it travels through our population. It can follow the epidemiology of it, and so that too is new, correct; and so that is beginning to be established, and that's something we will require from this point on. So that's an entirely fresh segment of the market being brought to genomics.

Doug Schenkel

analyst
#11

Good afternoon. I'd like to begin with a question about COVID, and then move to a broader one regarding the capital equipment outlook. So, on COVID first. Sure, it's hard to argue against the idea that the work you've done to advance COVID solutions in general deserves praise and broad recognition. Still, I believe there's enormous disagreement among clinicians and investors alike regarding just how significant a part Illumina next generation sequencing methods like SwabSeq can ultimately play as a genuine clinical testing answer, considering the complexity and logistical hurdles involved; we've all come across encouraging programs such as the ones being pursued by Ginkgo, yet we've also come across examples like the Broad Institute, where a huge number of sequencers are installed and the operation is highly advanced — possibly the most advanced anywhere — and even though they handle the largest COVID testing volume in Massachusetts, there are no plans to employ Illumina NGS for clinical sequencing. Given all that, how many labs do you believe will attempt to replicate what Ginkgo is doing, and for the purpose of sizing the market, would it be reasonable to say that the revenue opportunity per test for such an approach falls somewhere in the range of $1 to $3 per test? The second item I'd like to address is capital. It's encouraging to hear that clinical volumes are recovering and that people are returning to the lab, and clearly those are positive signals regarding the outlook for consumable demand, but instruments — on a year-over-year basis you performed better than many of us anticipated during the quarter, yet looking forward, what's your expectation, like how are you approaching the second half? Do you expect that labs, even if they come back and resume activity, will lean toward holding off somewhat on capital spending whenever they can, simply because of the uncertainty in the environment? Thank you.

Francis deSouza

executive
#12

Thanks, Doug. Let me work through the different parts of that question. The first portion concerned the actual role of NGS in COVID testing and what sort of part NGS will play, given that most testing is performed on PCR and always has been. So I'll begin there, then I'll address capital equipment; regarding COVID, once more, when I consider <<inaudible>>, it spans research, diagnostics, screening, and surveillance. Research, without a doubt — research projects are beginning to come online that are ideally matched to NGS rather than PCR. So every project I mentioned, really, they're new, they're additive, and they require NGS. And so whether that's GMI in Ireland or any of the other projects I brought up, those will run on NGS and will scale up throughout the year. When it comes to diagnostics, the initial round of testing was undeniably carried out using PCR. Therefore, given that the world had to expand testing capacity at an extremely rapid pace, it made complete sense that the entire first-wave scale-up relied on PCR. Now, why is NGS entering the picture? There are several factors behind this. First, certain areas are hitting capacity limits, correct? When we speak with labs — and you'll certainly come across this — even within the United States, the turnaround times for testing right now can exceed 10 days, and if you ask the labs what's causing that, they'll point to supply chain constraints, since every PCR testing service is vying for some of the same components within the supply chain. As a result, labs are approaching us about finding a testing approach that isn't competing for those identical supply chain resources. That's precisely where NGS fits in, and that's why they anticipate a fairly substantial demand for testing. We spoke with one lab, and they told us that on any given day they'll reject 20,000 people seeking tests simply because capacity isn't available; so there's obviously a need for a sizable system that isn't competing for the same supply chain; that's one factor driving us into diagnostic testing. A further factor pulling us into diagnostic testing is that in certain situations, people are seeking additional information. They don't merely want a yes or no diagnosis — they actually want several things. First, they may want a confirmatory test; for instance, if someone tests positive on PCR, in some cases they want confirmatory testing, they want to extract more information from the viral genome for <<inaudible>> data to obtain transmission information, so they can help guide policy decisions. And then in certain cases they run a particular percentage of the negatives just to verify that a false negative issue isn't occurring; and for that reason as well, they're seeking to expand their NGS capacity. So those are a few of the factors behind why we're being pulled into diagnostic testing, and you asked about SwabSeq versus COVIDSeq and frankly, obviously we support them all. SwabSeq was created to deliver a rapid diagnostic yes or no answer, correct. So it's a less expensive test and it does provide that yes-no answer, and there are various versions of SwabSeq being deployed by different customers of ours. You asked about the economics — you can think about it as depending on the version, it's roughly in the low to mid-single digits per test that comes to Illumina. If the customer is using COVIDSeq, you should think of it as a $20 test, for example, that comes to Illumina; and so, those are sort of the drivers behind why NGS is being pulled into the diagnostics section. So to assist with that, clearly, we created COVIDSeq and basically rolled it out toward the close of Q2. And we have just submitted for the EUA amendment so that the workflow becomes less complex and so that COVIDSeq can be performed on NextSeq, which lets smaller laboratories now carry out COVID testing. Regarding your following question — the remaining two areas where we're being drawn into COVID. So we mentioned research, we mentioned diagnostics, and we're being drawn into screening, and once more the concept there is to screen a healthy population, at very large scale, and so a number of our customers, as we discussed during the call, are seeking to apply NGS for that high-scale testing. It's early, some exciting pilots are underway, and we're observing how they turn out. And then for surveillance, that's something that truly can only be done on NGS. It isn't something achievable on PCR. Because what you're after with surveillance is to identify a pathogen outbreak as it occurs, and so for that, you actually must obtain the sequence of the pathogen. And then likewise with surveillance, you want to follow the transmission of the pathogen, and for that, you once more need the virus's genome, beyond what a PCR test can provide; and so surveillance is the genuine need that is uniquely suited for NGS. When it comes to capital equipment; I'm going to hand it over to Sam.

Sam Samad

executive
#13

Yeah, if I could just come in for a moment there, Doug, regarding capital — first off, I'm really encouraged by what we saw from NextSeq 2000 in Q2, both the results and the performance. It actually came in ahead of what we'd anticipated, and honestly, the response we're getting from customers has been terrific. Another thing we're hearing from customers is that there have been absolutely no outright cancellations of capital equipment, or really any lack of need for capacity. What they're doing is pushing back certain purchases, which makes sense given the uncertainty — they've been dealing with some fairly significant closures — and we also observed that with consumables, where inventories were drawn down during Q2. So delays are occurring, but cancellations are not. Customers remain interested, and as far as our expectations for the second half go, we're definitely anticipating a sequential rise in the revenue we expect from instruments, and clearly in placements too.

Dan Brennan

analyst
#14

Thanks a lot, and I appreciate you taking my questions. I have a few, and I'll combine them. The first concerns the clinical market. I realize the gain you anticipate for Q2 is relatively small. From what I can tell, though, much of the information coming out of hospitals shows a more pronounced uptick during the quarter, and the prospects look stronger. So I'd like to know why, in your view, clinical NGS isn't improving more quickly — that's my first point. Second, regarding pricing, can you expand on that a bit? Perhaps the goal is to unlock the lower end of the market by bringing a $600 offering down to smaller labs. Do you think that might spark a NovaSeq upgrade cycle as funding conditions improve somewhat? Then, for my third question, returning to COVID: I'm curious about screening. My sense is that now is the moment, since schools are preparing to reopen over the next few weeks. So when you mention possibly the fourth quarter as the point where this starts feeling more tangible for you, what's been slowing things down on the screening side from your perspective? And could you give us a bit more detail on your funnel? Francis, I know you brought up Delaware — you mentioned there's significant interest there — but can you share anything about what the screening opportunity looks like and what you're hearing from customers? Thanks.

Francis deSouza

executive
#15

Absolutely. Thanks, Dan. Let's begin with the clinical market — the forces at play there and the reasons it isn't moving quicker. The way I see it, the clinical market is really two distinct markets, correct? When you examine the NIPT situation, that segment has held up pretty well. Take the Americas as an example—between the first and second quarters, the NIPT market there expanded sequentially. Total revenues declined, yet NIPT still grew. So one portion of the clinical market, specifically NIPT, has shown real staying power, and that pattern holds steady. In the oncology space, the situation is that while it holds up better than the research market, it's weaker when it comes to NIPT. What's going on here—and this pattern is showing up on a wider scale—is that individuals are avoiding cancer screenings, which means fewer diagnoses are being made. It isn't that cancer incidence has dropped compared to earlier; rather, people simply aren't showing up for appointments. That's a tragedy for humanity, and for our business it translates into a slowdown in the oncology market. So the cancer situation isn't disappearing, so eventually we anticipate folks will head in for screening and will want testing done in order to be matched with the right treatment; therefore, within oncology there's probably some catch-up that has to occur at this point. Sadly it won't benefit everyone, yet some catch-up does need to occur. So those are the dynamics at play in the clinical market; regarding NIPT, somewhat more resilience, and oncology has some resilience too, though definitely not to the degree seen on the NIPT side; when it comes to the new NovaSeq pricing, that $600 dollar genome. So with this kit, the aim is to bring that $600 genome within easier reach for the folks we serve at Illumina. The way we see it, that frees customers to scope out more ambitious work when they're putting together grant proposals. The research market is really the target here — single cell work, going deeper on sequencing, bigger cohorts, whatever it may be — and we wanted that price point sitting in their minds as they map out projects for the time when they're back in the lab. My sense is this gives a modest lift to the economics for some of the smaller core labs that are still running HiSeqs and haven't moved over to NovaSeq yet. I'd say it makes those economics look even more attractive. So I'd say that's going to give a bit of a lift where the upgrade cycle is concerned. Now, on the screening side, unfortunately the need for screening isn't going to go away in the next few weeks just because people are heading back to school. I had a conversation with someone who heads up public health <<inaudible>>, an American, and the two of us are more or less on the same page that we'll be dealing with this for a minimum of a year, maybe a year to two years. The reason is that even in the best case, we're talking about a vaccine becoming available near the end of this year, and after that, there's going to be a gap between availability and wide deployment. So for that stretch of time, there will be a real requirement to make sure schools are safe and workplaces are safe, and that is what creates the demand for screening. I believe that demand for screening will continue to unfold even as we move toward roughly the midpoint of next year. We've already talked about a single case that is being introduced. Quite a few customers of ours are pursuing their own screening programs, and it's up to them to speak publicly about those efforts.

Puneet Souda

analyst
#16

Yes, hello, Francis. Thank you. I appreciate you fielding this. So I realize some of this ground has already been touched on, but I'd like to drill into one central issue. Traditionally, Illumina's growth has come through demand elasticity, and that is what has carried you into numerous markets — we've witnessed many markets broaden thanks to that demand elasticity. In fact, you were the earliest to merge into certain markets, whole-genome sequencing among them, and you propelled that market's expansion. So I'm just beginning to grasp, when you consider the coming couple of years, do you view COVID research, COVID testing, and COVID surveillance — and on surveillance, I fully concur that sequencing is absolutely essential to pursue some of these, as it were — but do you believe these markets can genuinely generate that demand elasticity for Illumina, and that down to $20 per test? Obviously, you see TCR antigen and other solutions at point of care arriving in these markets within roughly the next year. So I'm just attempting to obtain your perspective on how you foresee demand elasticity unfolding for Illumina here. Thank you.

Francis deSouza

executive
#17

Yes. Thank you, Puneet. So. I believe the various segments of the COVID market are — require distinct price points, and essentially what we're aiming to do is ensure we provide the correct offering at the correct price point to bring the various segments of the market to life. So allow me to be more precise. When we examine the diagnostic segment of the market, there you do require price points at which labs can provide a test at $75 to $100, which is where reimbursement stands, and still operate a viable business. And so in that case, something such as COVIDSeq, where the cost to them for Illumina reagents is $20, or SwabSeq, where it falls in the single-digit dollars, is precisely the right match. And so that's the price point that unlocks — that opens up that market for NGS. Now that market was never an NGS market. So this is entirely incremental to NGS; that was a PCR market; and so all of this represents new dollars now available to NGS, and to open up that market, you need a test at the $75 to $100 price point. And so for Illumina, that's either roughly low to mid-single digits or $20 a test, but that's a large test. Similarly with screening, you need that same price point, and you may even, with pulling, be able to reach lower price points in that market, and that's the price point required to activate those — markets. Screening could be a very large market, and it requires that kind of price point. When it comes to research and surveillance, a higher price point can be supported. In that segment, I believe $600 for a genome is the appropriate kind of price point — if you're running cohorts that aren't counted in the millions but rather in the thousands or tens of thousands, then $600 makes sense, and it sort of switches that market on, so that's our thinking for the research market. For surveillance, the price could actually be a bit higher, since once again you're not discussing millions of samples. So that's how we're approaching the various markets, with distinct offerings at distinct price points, in order to activate each of them.

Derik De Bruin

analyst
#18

Hello, and good afternoon. I'd like to ask about what you said regarding stockpiles getting reduced during Q3, or perhaps that happened in Q2. What's the current situation? Also, are further reductions anticipated in Q3, or might there be room for some rebound in spending as things recover? Let me also revisit the topic of academia and the government sector. We've spoken with individuals who mention strain on charitable giving and university funds, and we've observed several entities, including the ACS <<inaudible>>, that are trimming their expenditures. I realize a substantial sum flows into backing certain sequencing facilities and biomedical research institutes. So I'm curious what you're picking up regarding possible staff reductions and similar issues within academia. That leads into a separate inquiry: do you foresee any resurgence or a rush of budgets being used up during Q4? Thank you.

Sam Samad

executive
#19

All right. Let me address the inventory situation, Derik, and I appreciate your question. Then I'll turn things over to Francis to discuss the academic trends you brought up. Regarding stockpiles, to begin with, Q2 unfolded pretty much the way we anticipated on several fronts. I'd describe the instrument segment as positive, boosted by NextSeq 2000. For sequencing consumables, the area where results fell short of our expectations was research, and we attribute that to inventory—specifically, what we suspect is a reduction of stockpiles among those customers. From our discussions with them, this seems to stem from a few factors: the lack of clarity, ongoing shutdowns, continued unpredictability about what lies ahead, and the improved reliability of supply chains, which gives them greater confidence that disruptions won't occur, meaning they can obtain stock whenever required rather than accumulating it. So, looking at the activity levels in Q2, they matched what we had projected, yet a clear shortfall emerged in research because customers there were using up their stored supplies. You're asking what we're observing regarding how many months of inventory customers are holding, and how we think this pattern will unfold across the coming quarters. That's difficult to forecast, Derik—whether we'll see a restart, or a shift in Q3 or Q4. Honestly, that kind of visibility isn't available to us. What we're looking at is activity levels serving as an indicator of how sequencing consumables will grow, quarter by quarter, over the coming few quarters. And then, as we mentioned during the prepared remarks, we anticipate a modest uptick in activity levels across both clinical and research in Q3. However, when it comes to forecasting inventory or forecasting how customers will behave around building up or drawing down stock, that's genuinely hard to address right now. It's simpler to just walk through what happened in Q2 the way we did.

Francis deSouza

executive
#20

Right. So when it comes to funding from academia and also government sources, what we're observing is that in certain situations, researchers are being given additional time to utilize their academic grants. As a result, that might extend things somewhat in terms of how long a project runs, since individuals are staying at home and have more time available to actually draw on those funds. So that's something we're certainly noticing. What we're also noticing, however, is that additional dollars are flowing toward genomics-focused COVID studies rather than fewer, and this is arriving from a number of the standard places; for instance, I mentioned the proposal to boost NIH funding for the coming year by $5.5 million, which includes a raise of slightly more than $650 million for NHGRI — that's the proposal for NCRI. Beyond that, we're also observing dollars arriving for research and surveillance tied to COVID from places like philanthropies. In the case of the contribution we made to the 10 countries in Africa for the African CDC, we collaborated with one of the biggest philanthropic organizations in the US, plus another based in Asia, to attempt to assist in rolling out this worldwide surveillance network. We're additionally seeing organizations that typically don't finance genomics efforts. For instance, there's a rather intriguing partnership involving a broadening of ties between Microsoft and Adaptive, focused on grasping the immune system's response to COVID. So on the whole, we continue to observe enthusiasm for government funding, academic funding, and philanthropic funding connected to that COVID genomics research.

Jack Meehan

analyst
#21

Thanks. I had a few extra follow-ups. First, regarding NGS consumables — I'm not certain how much visibility you have on this, but what's your estimate for how long research labs will need to return to 100%? Some customers have told us they believe they can make up for the shutdowns by the end of the year. Does that seem realistic to you or not? Then, a follow-up about the clinical side, with COVIDSeq being rolled out on the NextSeq instrument. Could you update us on what the turnaround time for testing will be, and how that might address COVID-19 requirements? Thanks.

Sam Samad

executive
#22

I'll briefly address the research ramp you brought up, Jack, and thanks for asking. Francis can cover COVIDSeq and the NextSeq turnaround. Once more, at this point everything rests on assumptions and hinges on numerous factors concerning the virus, possible shelter in place measures, and as happened in Q2, we were headed the right way and then the situation reversed — I mean here in the US regarding the virus response. But as far as what we expect, Jack, again as we said before, we anticipate an improvement. During Q2 our average run rates stood at 65%. That serves as a proxy — basically activity levels on sequencers linked to our proactive network and the base space — and we anticipate that rising in Q3, plus a modest sequential rise in Q4. As for reaching 100%, I don't have an answer. At this stage that's simply beyond what we can see. Still, I think you ought to view this as steady, modest gains in activity levels going forward, which also holds for clinical — but that answers your Research question.

Francis deSouza

executive
#23

Right. And then, Jack, regarding what you asked about how long things take with NextSeq, clearly it varies based on the workflow at the sites of our customers who are bringing COVIDSeq and NextSeq in-house <<inaudible>>. The goal, naturally, is to provide a test that makes it possible to turn things around within that 24-hour window, though ultimately it comes down to the customer.

Jacquie Ross

executive
#24

Appreciate that, Mike. Just to note, folks can access a webcast replay of this session over in the Investors portion of our site, and the dial-in details are also included in the press release we put out today. We're glad you could be with us. That wraps things up for this call, and we're eager to reconnect with everyone for our next update once the third fiscal quarter has ended.

Operator

operator
#25

That wraps up the conference call for today, everyone. We appreciate your participation. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.